Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480706 | 1.00 | MDM4 (0.46) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL31000753 | 1.00 | MDM4 (0.46) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL5913024 | 1.00 | MDM4 (0.46) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL8018654 | 1.00 | MDM4 (0.46) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL31000751 | 1.00 | MDM4 (0.46) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL31000614 | 0.87 | CASP3 (0.43) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL31000582 | 0.87 | FFAR1 (0.43) | MDM4TP53CASP3PIN1MDM2 | |
| SCHEMBL31000535 | 0.85 | HDAC3 (0.43) | MDM4TP53CASP3PIN1KMT2A | |
| SCHEMBL31000490 | 0.85 | MDM4 (0.43) | MDM4TP53CASP3PIN1MDM2 | |
| SCHEMBL6225058 | 0.84 | TACR1 (0.44) | PIN1KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1738798-A | Indole derivatives as somatostatin agonists or antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-22 | — | — | CN | disclosed |
| US-20050245571-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1437351-A1 | AMINE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245571-A1 | Amine derivative | NPY1R, SSTR1, SSTR5 | MDM4 4828/4885TP53 2783/4885CASP3 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.